NZS Capital LLC Boosts Position in Repligen Co. (NASDAQ:RGEN)

NZS Capital LLC grew its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 4.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 133,694 shares of the biotechnology company's stock after buying an additional 5,855 shares during the quarter. NZS Capital LLC owned 0.24% of Repligen worth $19,244,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its holdings in Repligen by 11.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock valued at $1,027,165,000 after acquiring an additional 743,815 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Repligen by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company's stock valued at $734,251,000 after purchasing an additional 56,723 shares during the last quarter. Champlain Investment Partners LLC increased its stake in shares of Repligen by 8.6% during the 4th quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company's stock worth $222,176,000 after purchasing an additional 122,595 shares in the last quarter. Alliancebernstein L.P. raised its position in shares of Repligen by 23.4% during the 4th quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company's stock worth $145,508,000 after purchasing an additional 191,439 shares during the last quarter. Finally, Conestoga Capital Advisors LLC raised its position in shares of Repligen by 0.7% during the 4th quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company's stock worth $136,395,000 after purchasing an additional 6,872 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Insider Transactions at Repligen

In other Repligen news, Director Margaret Pax purchased 250 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This represents a 31.53 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.20% of the company's stock.

Analyst Ratings Changes

Several equities analysts have weighed in on RGEN shares. TD Cowen began coverage on Repligen in a research report on Monday, February 10th. They set a "buy" rating and a $200.00 price target for the company. JPMorgan Chase & Co. lifted their price objective on Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Canaccord Genuity Group cut their target price on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research note on Wednesday, April 16th. Evercore ISI started coverage on shares of Repligen in a research note on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price target on the stock. Finally, Royal Bank of Canada boosted their price objective on shares of Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a research report on Friday, February 21st. One analyst has rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Repligen currently has an average rating of "Hold" and an average target price of $176.82.

Repligen Stock Performance

NASDAQ:RGEN opened at $144.75 on Friday. The company has a market cap of $8.13 billion, a P/E ratio of -283.82, a P/E/G ratio of 4.54 and a beta of 1.27. The firm's 50 day moving average is $139.80 and its two-hundred day moving average is $145.86. Repligen Co. has a fifty-two week low of $102.97 and a fifty-two week high of $182.52. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Analysts expect that Repligen Co. will post 1.72 EPS for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.